RJFSA
SMMT icon

Raymond James Financial Services Advisors’s Summit Therapeutics SMMT Stock Holding History

Raymond James Financial Services Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-15,000
Closed -$33K – 2807
2018
Q3 		$33K Hold
15,000
– – ﹤0.01% 2741
2018
Q2 		$37K Buy
+15,000
New +$192K ﹤0.01% 2686

Other funds holding SMMT

LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return

Raymond James Financial Services Advisors's SMMT Position: Q4 2018 in Review

Raymond James Financial Services Advisors sold out of Summit Therapeutics (SMMT) in Q4 2018, closing a stake of 15,000 shares — an estimated $33K sold.

Raymond James Financial Services Advisors first reported a position in SMMT in Q2 2018 and held it in 2 quarters. The position peaked at $37K in Q2 2018. 13 funds tracked by Wall St. Rank hold SMMT as of Q4 2018.

  • Raymond James Financial Services Advisors reported no remaining Summit Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 15,000 Summit Therapeutics shares in Q4 2018, an estimated $33K.
  • Raymond James Financial Services Advisors first reported a position in Summit Therapeutics in Q2 2018 and held it in 2 quarters.
  • Raymond James Financial Services Advisors's Summit Therapeutics position peaked at $37K in Q2 2018.
  • 13 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2018.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2018, filed 11 Feb 2019.